ro3

RO3 is a selective antagonist of homomeric P2X3 and heteromeric P2X2/3 receptor

Ro3280 (Ro5203280) is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).

RO320-2947 001 is a bioactive chemical.

TO-PRO3 iodide is a nucleic acid stain that can stain the nucleus of cells in different states, including living, early apoptotic, and necrotic cells.

RO3244794 is a selective prostacyclin (IP) receptor antagonist that can be used to study liver injury.

RO314724 is a HDAC inhibitor. RO314724 is also a a reversible, tightly binding, MMP inhibitor with a Ki of 26 nm. Matrix metalloproteinases (MMPs) belong to the key enzymes of the proteolytic destruction of cartilage matrix during chronic rheumatic diseases. Ro314724 displayed MMP-proteoglycanase inhibitory activity both in vitro and ex vivo and proved to be not harmful to the morphology, viability and proteoglycan biosynthesis of bovine articular cartilage explants.

[Leu31,Pro34]-Neuropeptide Y(human,rat) TFA acts as a specific agonist for the neuropeptide Y Y1 receptor and also activates Y4 and Y5 receptors, elevating blood pressure in anesthetized rats and enhancing food intake [1] [2].

(Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is a stable and specific full agonist for the human GIP receptor (hGIPR) with a high binding affinity (K i K d values of 0.90 nM), demonstrating efficacy in targeting hGIPR, and is thus suitable for obesity-related diabetes research [1] [2].

(Pro34)-Peptide YY (human) is a highly Y1-selective full agonist of Peptide YY neuropeptide Y receptors [1].

(Leu31,Pro34)-Peptide YY (human) is a derivative of Peptide YY that acts as a potent and selective Y1 receptor agonist, with a dissociation constant (KD) of 1.0 nM [1].

(Leu31,Pro34)-Peptide YY (human) (TFA) is the trifluoroacetic acid (TFA) form of (Leu31,Pro34)-Peptide YY (human), a derivative of Peptide YY that acts as a potent and selective Y1 agonist, exhibiting a dissociation constant (K D) of 1.0 nM [1].

[D-Phe2,6, Pro3]-LH-RH is a potent antagonist of luteinizing hormone-releasing hormone (LHRH).

High affinity neuropeptide Y Y1 receptor agonist (Ki = 0.39 nM). Also shows affinity for Y4 and Y5 receptors.

GIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insul

[Pro3]-GIP (Mouse) acetate is mouse [Pro3]-GIP. [Pro3]-GIP is a GIP receptor antagonist.

High affinity rat GIP receptor partial agonist (Kd = 13 nM). Increases cAMP accumulation in COS-7 cells transfected with rat GIP receptor, while also acting as a competitive antagonist of GIP.

High affinity neuropeptide Y Y1 receptor agonist

[Pro34]Neuropeptide Y, porcine functions as a selective agonist for the NPY (Y1) receptor and induces vasoconstriction in the guinea pig's caval vein [1].

Bufuralol (Ro 3-4787) is an orally active β-adrenergic receptor blocker with a certain degree of sympathomimetic effects and can be used to study cardiovascular diseases.